Search

Bruce R Ksander

from Belmont, MA
Age ~68
Get Report
Also known as:
Bruce Dr Ksander, Bruce R Sander
Related to:
Karen K Ettelson, 69William S Ettelson, 64Louis KsanderScott Ksander, 72Jeffrey Ksander, 40
Connected to:
Jill S Ksanznak, 61Shelly A Ksanznak, 73Carole Ksas, 51Elena S Ksenofontova, 39Donald C Ksepka, 71Bhupendra Kshatriya, 73Kishor S Kshatriya, 54Nath P Kshemendra, 61Anil L Kshirsagar, 72Chinmay Kshirsagar, 32

Bruce Ksander Phones & Addresses

  • Belmont, MA
  • 4 Longfellow St, Boston, MA 02114 (617) 670-1058
  • 126 Banyan Dr, Ormond Beach, FL 32176
  • 21 Chestnut St, Salem, MA 01970
  • Swampscott, MA
  • Miami, FL

Work

Company: Harvard university Position: Associate professor

Industries

Higher Education

Resumes

Resumes

Bruce Ksander Photo 1

Associate Professor

View page
Location:
20 Staniford St, Boston, MA 02114
Industry:
Higher Education
Work:
Harvard University
Associate Professor

Publications

Isbn (Books And Publications)

Immunology of Ocular Tumors

View page
Author

Bruce R. Ksander

ISBN #

9026519311

Uveal Melanoma: A Model for Exploring Fundamental Cancer Biology

View page
Author

Bruce R. Ksander

ISBN #

9026519621

Us Patents

Tumor Cells From Immune Privileged Sites As Base Cells For Cell-Based Cancer Vaccines

View page
US Patent:
8444965, May 21, 2013
Filed:
Sep 23, 2010
Appl. No.:
12/889043
Inventors:
Jacobus J. Bosch - Baltimore MD, US
Bruce R. Ksander - Belmont MA, US
Assignee:
University of Maryland, Baltimore County - Baltimore MD
International Classification:
A61K 39/00
C12N 5/0783
C12N 5/09
C12N 15/00
C12N 15/867
C12N 15/87
US Classification:
424 9321, 424 937, 424 9371, 435325, 435455, 435456, 435465
Abstract:
The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.

Tumor Cells From Immune Privileged Sites As Base Cells For Cell-Based Cancer Vaccines

View page
US Patent:
20080206288, Aug 28, 2008
Filed:
Jan 16, 2008
Appl. No.:
12/015116
Inventors:
Jacobus J. Bosch - Baltimore MD, US
Bruce R. Ksander - Belmont MA, US
International Classification:
A61K 39/00
A61K 35/12
US Classification:
4242771, 424 937
Abstract:
The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.

Aav2-Mediated Gene Delivery Of Sfasl As A Neuroprotective Therapy In Glaucoma

View page
US Patent:
20190240353, Aug 8, 2019
Filed:
Jul 5, 2017
Appl. No.:
16/315362
Inventors:
- Boston MA, US
Bruce Ksander - Boston MA, US
Assignee:
University of Massachusetts - Boston MA
Massachusetts Eye and Ear Infirmary - Boston MA
International Classification:
A61K 48/00
A61P 27/06
C07K 14/705
A61K 45/06
C12N 7/00
A61K 9/00
A61K 38/17
Abstract:
Methods for treating glaucoma and/or Fas ligand-dependent inflammatory conditions in a subject using soluble Fas ligand (sFasL) or a fragment thereof, which may be rAAV-mediated delivery of sFasL or a fragment thereof to a subject.
Control profile
Bruce R Ksander from Belmont, MA, age ~68 Get Report